UK Insurtech Funding Is Defying the Global Slowdown — Here's Why
Global insurtech investors have been retreating for years. Deals over $100 million plummeted 85% in the first half of 2025 alone, falling to just $275 million from $1.9 billion in the second half of 2024. The sector's 2021 peak $16.6 billion across 867 deals now looks like a different market entirely; by Q1 2025, total funding had fallen to roughly $1.8 billion.
UK insurtech funding hasn't escaped that pullback either, but it's holding up in a way the wider global numbers don't fully explain. According to CB Insights, 11% of equity deals into UK-based insurtech companies in 2025 went to startups ranked in the global top 1% by predictive success scoring more than double the 5% rate across the UK's entire startup ecosystem. In a shrinking market, UK insurtech investors are getting more selective, not less active, and they're picking winners at an unusually high rate.
The global pullback, and what's different about the UK
The scale of the global insurtech correction is worth sitting with. Late-stage insurtech funding fell hardest average round sizes dropped 36%, from $62.5 million to $40 million while early-stage funding stayed comparatively flat at around $3 million per round. Investors pulled back from big, speculative later-stage bets and concentrated instead on companies that had already proven their unit economics.
That's precisely the environment where UK insurtech funding has found its footing. CB Insights' analysis of the 25 most active backers of UK insurtech startups between 2021 and 2025 found a market getting structurally tighter: fewer active investors, sharper competition for deals, and falling median early-stage deal sizes even as the broader UK venture market moved in the opposite direction. The read isn't that UK insurtech is immune to the slowdown. It's that a smaller group of specialist investors has become very good at identifying the startups worth backing inside it.
Zego and the UK's first insurtech unicorn
The clearest proof point for UK insurtech funding working at scale is Zego, which became the UK's first insurtech unicorn at a $1.1 billion valuation after DST Global led its $150 million Series C. DST typically writes large, late-stage checks for category leaders with demonstrated market share rather than backing early, unproven bets which makes its decision to lead Zego's round a meaningful signal about where global capital sees UK insurtech heading.
Zego's rise also shaped the investor base underneath it. Balderton Capital, which backed Zego from seed through to unicorn status, has become one of Europe's most active Series A investors in the space, specifically looking for insurtech companies with strong network effects and market-leading retention data a more selective mandate than "insurtech" as a category alone would suggest.
Where the money is actually landing now
Two recent UK deals show what's currently winning capital. hyperexponential, which builds pricing software for commercial insurers, raised a $73 million Series B the largest UK insurtech round of its funding cycle led by Battery Ventures. Battery's partner Marcus Ryu, the former CEO of insurance software company Guidewire, joined hyperexponential's board post-investment, giving the round a strategic weight beyond the capital itself.
Marshmallow, meanwhile, secured a $90 million Series C with BlackRock participating via managed funds one of the largest asset-manager investments into a UK insurtech to date. Asset managers don't typically chase early, high-growth speculation; their involvement tends to signal a company with a visible, credible path to sustained profitability rather than just growth.
Zooming out, Seedtable's tracking of the UK insurtech landscape shows the top 21 startups have raised a combined $1.6 billion, averaging $73.9 million per company. Typical early-stage UK insurtech checks run between £500,000 and £7 million, with total rounds sized from £1 million up to £15 million a range that reflects a market still funding real bets, just more deliberately than during the 2021 peak.
What this means if you're building here
The practical read for founders is that UK insurtech funding is rewarding proof over promise right now. The deals landing capital Zego's retention data, hyperexponential's enterprise pricing traction, Marshmallow's profitability trajectory all lead with a specific, demonstrable metric rather than a category story. A pitch built around "insurtech is a big market" is competing for a shrinking pool of later-stage capital against companies that can already show investors the numbers that matter to them specifically.
It's also worth engaging early with the UK's dedicated support infrastructure rather than treating insurtech as a subset of general fintech. Programmes like Norton Rose Fulbright's Insurathon which has delivered over £325,000 in legal and investment-related support to UK insurtech startups since 2017 exist specifically because insurance carries regulatory complexity that generalist accelerators aren't built to handle. Getting regulatory readiness right early is increasingly part of what separates the startups landing top-tier UK insurtech funding from those that stall before they get the chance to pitch for it.
FAQ
1. Is UK insurtech funding growing or shrinking?
Global insurtech funding has fallen sharply since its 2021 peak, and UK insurtech funding has tightened too fewer active investors and lower median early-stage deal sizes in 2025. But UK insurtech is punching above its weight on quality: 11% of its 2025 equity deals went to top 1%-ranked startups by CB Insights' Mosaic Score, versus 5% across the wider UK startup ecosystem.
2. Which is the UK's biggest insurtech company?
Zego is the UK's first insurtech unicorn, reaching a $1.1 billion valuation after DST Global led its $150 million Series C. The top 21 UK insurtech startups tracked by Seedtable have raised a combined $1.6 billion.
3. What size are typical UK insurtech funding rounds?
Early-stage checks typically range from £500,000 to £7 million, with total round sizes between £1 million and £15 million, according to thatround.com. Larger, later-stage rounds like hyperexponential's $73 million Series B and Marshmallow's $90 million Series C have become rarer as investors concentrate on companies with proven unit economics.
Sources: FinTech Global, CB Insights (via Crowdfund Insider), Seedtable, thatround.com, insights150.com, Norton Rose Fulbright. Figures reflect the most recent available data at the time of writing (August 2026). This piece was adapted by the EP+ editorial team — our company profile is also listed on Crunchbase.

Comments
Post a Comment